StockNews.AI
TNON
StockNews.AI
152 days

Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results

1. TNON reports $3.3 million revenue for 2024, a 12% increase yearly. 2. National launch of Catamaran SE scheduled for mid-2025 could boost growth.

2m saved
Insight
Article

FAQ

Why Bullish?

The increase in revenue points to positive momentum, similar to past growth patterns in medical tech stocks that drive investor confidence.

How important is it?

The reported revenue growth and upcoming product launch enhance TNON's market position and investment attractiveness.

Why Long Term?

The anticipated national launch in 2025 could establish a strong market presence, positively affecting TNON's long-term prospects.

Related Companies

SMDICOHRFDX
~ Full Year 2024 Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~ ~ Interim Analysis from MAINSAIL Study Reinforces Safety Profile, Effectiveness and Confirmation of Fusion ~ ~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and International Patents ~ ~ Introduced Catamaran SE Platform and Successfully Completed Initial Clinical Procedures ~ ~ National Commercial Launch of Catamaran SE in Mid-2025 ~ LOS GATOS, CA / ACCESS Newswire / March 20, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the fourth quarter and year ended December 31, 2024. Financial Results and Business Updates Fourth Quarter 2024 Results: Revenue of $0.8 million, in line with the fourth quarter of 2023.

Related News